On October 19, 2017 Propanc Biopharma Inc. (OTCQB: PPCB) (“Propanc Biopharma” or “the Company”), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, reported that key scientific data has been published in a peer reviewed journal, Scientific Reports, demonstrating a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen provide potent anti-tumor efficacy in pancreatic and ovarian cancers (Press release, Propanc, OCT 19, 2017, View Source [SID1234521051]). From the publishers of Nature, it is an online, open access journal, which publishes primary research from all areas of the natural and clinical sciences.

Published data from the Company’s R&D program were conducted with Universities of Jaén and Granada and University Hospital, Spain, vivoPharm Pty Ltd, Australia, and the Dove Clinic for Integrated Medicine, UK. Highlights include the anti-angiogenic effect of PRP by using fibrous capsule formation assays, as well as cell invasion and wound healing assays, along with the analysis of epithelial to mesenchymal transition (EMT) markers performed on human cancer cells treated with PRP.

Of particular note in the publication is the evaluation of clinical efficacy of a suppository formulation of pancreatic proenzymes in the context of a UK Pharmaceutical Specials Scheme, led by Dr Kenyon, where 19 from 46 patients (41.3%) with late stage cancers, most suffering from metastases, had a survival time significantly longer than the expected life span. For the whole set of cancer types, a mean survival of 9.0 months was significantly higher than their mean life expectancy, 5.6 months, in a one way ANOVA test (alpha = 0.05, P less than 0.05).

“We are delighted that our latest scientific paper shows the synergistic effects of our PRP formulation, which is proven to inhibit in vitro angiogenesis, tumour growth, cancer cell migration and invasiveness, and to be an effective and well tolerated in vivo anti-tumor treatment,” said Dr Julian Kenyon, Propanc Biopharma’s Chief Executive Officer. “Furthermore, the clinical efficacy of a suppository formulation containing both pancreatic proenzymes administered to late stage cancer patients during a compassionate use program in the UK and Australia confirms a mean survival significantly higher than mean life expectancy. Therefore, I believe PRP could have relevant oncological applications for the treatment of advanced or metastatic pancreatic cancer and advanced epithelial ovarian cancer, which are our initial target patient populations in our planned clinical development program.”

PRP is a solution for once daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen. Currently progressing towards First-In-Human studies, PRP aims to prevent tumor recurrence and metastasis from solid tumors. Eighty percent of all cancers are solid tumors and metastasis is the main cause of patient death from cancer. According to the World Health Organization, 8.2 million people died from cancer in 2012. Consequently, a report by IMS Health states innovative therapies are driving the global oncology market to meet demand, which is expected to reach $150 Billion by 2020. The Company’s initial target patient populations are pancreatic, ovarian and colorectal cancers, representing a combined market segment of $14 Billion predicted in 2020, by GBI Research.

To view Propanc Biopharma’s “Mechanism of Action” video on anti-cancer product candidate, PRP, please click on the following link: View Source

To be added to Propanc Biopharma’s email distribution list, please click on the following link: View Source and submit the online request form.

On October 19, 2017 Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, reported that the European Medicines Agency (EMA) has granted Orphan Drug Designation for G100, Immune Design’s investigational intratumoral therapy, for the treatment of follicular non-Hodgkin’s lymphoma (Press release, Immune Design, OCT 19, 2017, View Source [SID1234521040]).

The EMA orphan drug designation is assigned to products targeting the treatment of rare diseases, which are defined as having a prevalence of not more than 5 in 10,000 people in the European Union (EU). This designation provides the sponsor with certain benefits, including protocol assistance, reduced fees for regulatory activities and up to 10 years of market exclusivity in the EU upon marketing approval for the designated indication.

G100 has also been granted orphan drug designation by the U.S. Food and Drug Administration for the treatment of follicular non-Hodgkin’s lymphoma.

G100 is a product candidate from Immune Design’s GLAAS discovery platform. It contains a potent synthetic small molecule toll-like receptor-4 (TLR-4) agonist, Glucopyranosyl Lipid A (GLA), and is the lead product candidate in Immune Design’s Antigen Agnostic approach. G100 activates innate and adaptive immunity in the tumor microenvironment to generate an immune response against the tumor’s preexisting diverse set of antigens. A growing set of clinical and preclinical data have demonstrated the ability of G100 to activate tumor-infiltrating lymphocytes, macrophages and dendritic cells, and promote antigen-presentation and the recruitment of T cells to the tumor. The induction of local and systemic immune responses has been shown in preclinical studies to result in local and abscopal (shrinking of tumors outside the scope of the localized treatment) tumor control. Currently, G100 is being evaluated as both a monotherapy (with local radiation) and in combination with Merck’s anti-PD-1 agent, pembrolizumab, pursuant to a clinical collaboration with Merck, in a randomized Phase 1/2 clinical trial in patients with follicular non-Hodgkin’s lymphoma.

On October 19, 2019 INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”), reported that it will release its third quarter 2017 financial results on Thursday, Nov. 2, before the U.S. financial markets open(Press release, Insys Therapeutics, OCT 19, 2017, View Source [SID1234521027]).

Following the release of the financial results, Saeed Motahari, president and chief executive officer, and Andrew Long, chief financial officer, will host a conference call at 8:30 a.m. Eastern Daylight Time.

Investors, analysts and members of the media interested in listening to the live presentation are encouraged to join a webcast of the call available on the company’s website at View Source Interested parties may also participate in the call by dialing (844) 263-8304 (from inside the U.S.) or (213) 358-0958 (from outside the U.S.). A webcasted replay of the conference call will be available a few hours after the event through the INVESTORS section, under the NEWS & EVENTS tab for “Presentations.”

Halozyme Therapeutics, Inc. will webcast its Quarterly Update Conference Call for the third quarter 2017 on Tues., Nov. 7 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call (Press release, Halozyme, OCT 19, 2017, View Source [SID1234521026]).

The live call may be accessed by dialing (877) 410-5657 (domestic callers) or (334) 323-7224 (international callers) using passcode 769890. A telephone replay will be available after the call by dialing (877) 919-4059 (domestic callers) or (334) 323-0140 (international callers) using replay ID number 19320711.

On October 19, 2017 Esanex, Inc., a clinical stage company developing Heat Shock Protein inhibitors for the treatment of cancer, reported the first patient has been dosed in an open-label study of SNX-5422 added to ibrutinib in chronic lymphocytic leukemia (CLL) subjects with residual disease (clinicaltrials.gov ID#NCT02973399) (Press release, Esanex, OCT 19, 2017, View Source [SID1234521024]).

“Resistance to ibrutinib is a serious concern in CLL,” says Dr. Jennifer A. Woyach, M.D., The Ohio State University. “SNX-5422 is designed to attack cancer cells by a different, complementary mechanism, making their escape from cell death much harder. There is a critical need to develop drugs and drug combinations for the patients suffering from this life-threatening disease.”

The study is designed to investigate the safety of combining SNX-5422 and ibrutinib and provide information on whether the addition of SNX-5422 to an established dose of ibrutinib will provide clinical benefit in subjects who have stable, residual disease on ibrutinib alone. In each cycle, subjects will receive SNX-5422 (56 mg/m2) in the morning once every other day for 21 days (11 doses), followed by a 7-day period without SNX-5422 treatment. Subjects will continue to receive daily oral ibrutinib at their established dose level in the afternoon.

“The initiation of this clinical trial marks a major milestone for our Company,” said Steve Hall, Ph.D., president and CEO of Esanex. “The new mechanistic understanding of SNX-5422 that Esanex has uncovered, which differentiates our compound from other Hsp90 inhibitors, has enabled us to rationally approach monotherapy and select combination therapies for distinct indications. We believe we are only beginning to see the potential of SNX-5422 and Hsp90 inhibition as a treatment for cancer and possibly other diseases.”

About SNX-5422
SNX-5422 is a chemically unique, orally active Hsp90 inhibitor that has provided durable clinical responses in open label trials in non-small cell lung cancer (NSCLC) and neuroendocrine tumors (NET). The potential of SNX-5422 in hematologic cancers is currently being explored in a chronic lymphocytic leukemia (CLL) clinical trial. With approximately 200 patients treated to date, SNX-5422 has a well-established safety profile that supports studying it in combination with existing approved drugs in a variety of clinical settings.